title: AParadigm Shift: The New Novel Oral Anticoagulation Agents.
abstract: Atrial fibrillation (AF) is the most common arrhythmia and represents one-third of the arrhythmia-related hospital admissions in the developed countries. Embolic strokes associated with AF are more severe and disabling. Thromboembolic stroke prevention is a major goal in treatment of AF and Warfarin has successfully served this purpose for many years. Drug-drug interaction and regular monitoring with Warfarin pose a significant challenge where health care system has limited resources; and lack of a well-structured health system, hinders regular International Normalized Ratio (INR) monitoring. Novel oral anticoagulants (NOACs) have opened up a new exciting chapter in the field of anticoagulation in non-valvular atrial fibrillation (NVAF). This review discussed the landmark trials that led to the development of NOACs and explored the potentials of these new agents with simultaneous comparison of Warfarin.
authors: Department of Cardiology, Heart Failure and Transplant. Albert Einstein College of Medicine, New York, USA.
authors: Wajeeha
authors: W
authors: Saeed
authors: Department of Cardiology, Lankenau Medical Center, Wynnewood; Department of Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
authors: James F
authors: JF
authors: Burke
authors: Department of Cardiology, Lehigh Valley Hospital, Allentown, Pennsylvania, USA.
authors: Ghazi
authors: G
authors: Mirrani
authors: Department of Cardiology, Lankenau Medical Center, Wynnewood, Pennsylvania, USA.
authors: Minisha
authors: M
authors: Sirinivasa
authors: Department of Cardiology, Lankenau Medical Center, Wynnewood; Department of Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
authors: Usman
authors: U
authors: Nabi
authors: Department of Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
authors: Umar
authors: U
authors: Hayat
authors: Department of Cardiology, Cooper University Hospital, Rowan School of Medicine, Camden, New Jersey, USA.
authors: Zubair
authors: Z
authors: Khan
authors: Department of Cardiology, Cooper University Hospital, Rowan School of Medicine, Camden, New Jersey; Alpert School of Medicine of Brown University, Providence, Rhode Island, USA.
authors: Muhammad Rizwan
authors: MR
authors: Sardar
mesh_terms: D000284:Administration, Oral; D000925:Anticoagulants / Q000008:administration & dosage* / Q000494:pharmacology; D001281:Atrial Fibrillation / Q000150:complications / Q000188:drug therapy*; D001777:Blood Coagulation / Q000187:drug effects*; D004347:Drug Interactions; D016903:Drug Monitoring; D065427:Factor Xa Inhibitors / Q000008:administration & dosage* / Q000494:pharmacology; D006801:Humans; D019934:International Normalized Ratio; D020521:Stroke / Q000209:etiology / Q000517:prevention & control*; D016896:Treatment Outcome; D014859:Warfarin / Q000008:administration & dosage* / Q000494:pharmacology
chemical_list: D000925:Anticoagulants; D065427:Factor Xa Inhibitors; D014859:Warfarin